Literature DB >> 2624266

Prevalence of familial hypercholesterolemia in Johannesburg Jews.

H C Seftel1, S G Baker, T Jenkins, D Mendelsohn.   

Abstract

The prevalence of heterozygous familial hypercholesterolemia was determined in a representative sample of 403 young Jewish men resident in Johannesburg, South Africa. Preliminary screening by measurement of serum total cholesterol demonstrated that 25 of them had levels greater than or equal to 7.5 mmol/l (290 mg/dl). On the basis of subsequent clinical, biochemical, and family studies, 6 men, or about 1 in 67 of the total sample, were considered to be heterozygotes. This very high prevalence, about 7 times greater than that found in other Caucasian populations, is probably related to founder effect. It may help to explain the high frequency of coronary heart disease in Johannesburg Jews.

Entities:  

Mesh:

Year:  1989        PMID: 2624266     DOI: 10.1002/ajmg.1320340418

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  19 in total

1.  Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.

Authors:  Zahid Ahmad; Beverley Adams-Huet; Chiyuan Chen; Abhimanyu Garg
Journal:  Circ Cardiovasc Genet       Date:  2012-10-11

2.  Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews.

Authors:  R Durst; R Colombo; S Shpitzen; L B Avi; Y Friedlander; R Wexler; F J Raal; D A Marais; J C Defesche; M Y Mandelshtam; M J Kotze; E Leitersdorf; V Meiner
Journal:  Am J Hum Genet       Date:  2001-04-17       Impact factor: 11.025

3.  Increased expression of ApoE and protection from amyloid-beta toxicity in transmitochondrial cybrids with haplogroup K mtDNA.

Authors:  Kunal Thaker; Marilyn Chwa; Shari R Atilano; Pinar Coskun; Javier Cáceres-Del-Carpio; Nitin Udar; David S Boyer; S Michal Jazwinski; Michael V Miceli; Anthony B Nesburn; Baruch D Kuppermann; M Cristina Kenney
Journal:  Neurobiol Dis       Date:  2016-04-22       Impact factor: 5.996

Review 4.  The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.

Authors:  Faisal Alallaf; Fatima Amanullah H Nazar; Majed Alnefaie; Adel Almaymuni; Omran Mohammed Rashidi; Khalid Alhabib; Fahad Alnouri; Mohamed-Nabil Alama; Mohammad Athar; Zuhier Awan
Journal:  Open Cardiovasc Med J       Date:  2017-07-26

5.  Premature coronary heart disease and autosomal dominant hypercholesterolemia: Increased risk in women with LDLR mutations.

Authors:  Zahid Ahmad; Xilong Li; Jedrek Wosik; Preethi Mani; Joye Petr; George McLeod; Shatha Murad; Li Song; Beverley Adams-Huet; Abhimanyu Garg
Journal:  J Clin Lipidol       Date:  2015-09-25       Impact factor: 4.766

Review 6.  Genetics of familial hypercholesterolemia.

Authors:  Ariel Brautbar; Emili Leary; Kristen Rasmussen; Don P Wilson; Robert D Steiner; Salim Virani
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

7.  Molecular characterization of Iranian patients with possible familial hypercholesterolemia.

Authors:  E Farrokhi; F Shayesteh; S Asadi Mobarakeh; F Roghani Dehkordi; K Ghatreh Samani; M Hashemzadeh Chaleshtori
Journal:  Indian J Clin Biochem       Date:  2011-02-10

Review 8.  Familial hypercholesterolemia--epidemiology, diagnosis, and screening.

Authors:  Siddharth Singh; Vera Bittner
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 9.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

10.  A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews.

Authors:  V Meiner; D Landsberger; N Berkman; A Reshef; P Segal; H C Seftel; D R van der Westhuyzen; M S Jeenah; G A Coetzee; E Leitersdorf
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.